Holen Sie sich die Stockscreener-App
0.9326
9.59%
0.0816
Handel nachbörslich:
.88
-0.0526
-5.64%
Schlusskurs vom Vortag:
$0.851
Offen:
$0.901
24-Stunden-Volumen:
34,369
Relative Volume:
0.03
Marktkapitalisierung:
$3.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.35M
KGV:
-2.0274
EPS:
-0.46
Netto-Cashflow:
$-5.48M
1W Leistung:
+25.86%
1M Leistung:
+18.05%
6M Leistung:
+142.23%
1J Leistung:
+75.96%
1-Tages-Spanne:
$0.825
$0.9326
1-Wochen-Bereich:
$0.721
$0.9326
52-Wochen-Spanne:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Firmenname
Shuttle Pharmaceuticals Holdings Inc
Sektor
Telefon
(240) 403-4212
Adresse
401 PROFESSIONAL DRIVE, GAITHERSBURG
Vergleichen Sie SHPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.9326 | 3.42M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Shuttle Pharmaceuticals Holdings Inc Aktie (SHPH) Neueste Nachrichten
Tilray (TLRY) Stock Drops 5.11% Amidst Market Volatility - GuruFocus.com
EZFill Holdings, Inc. Enters Mobile Fueling Vendor Agreement with Amazon - Defense World
Shuttle Pharmaceuticals Holdings, Inc. Engages in Sponsored Research Agreement with UCSF - Defense World
Shuttle Pharma Enters into Sponsored Research Agreement - GlobeNewswire
Shuttle Pharmaceuticals Partners with UCSF for Breakthrough Prostate Cancer Diagnostic Development - StockTitan
Shuttle Pharmaceuticals stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
SHPH stock touches 52-week low at $0.75 amid market challenges - Investing.com UK
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA - GuruFocus.com
Likelihood of Approval and Phase Transition Success Rate ModelRopidoxuridine in Bile Duct Cancer (Cholangiocarcinoma) - GlobalData
Shuttle Pharmaceuticals Initiates Phase 2 Clinical Trial for Glioblastoma Treatment- - Defense World
Shuttle Pharmaceuticals stock hits 52-week low at $0.83 By Investing.com - Investing.com Canada
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma - TipRanks
Shuttle Pharmaceuticals Launches Phase 2 Trial for Breakthrough Glioblastoma Treatment | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Up - GuruFocus.com
Micro Cap Company Is Soaring On Phase 2 Trial Update - MSN
500: Something went wrong - Investing.com UK
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewswire
Shuttle Pharma Advances Phase 2 Trial, Secures $4.5M Funding for Cancer Treatment Study | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals’ $4.5 Million Common Stock Offering - Global Legal Chronicle
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News - MSN
Shuttle Pharma Raises $4.5M for Clinical Trials - TipRanks
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
Shuttle Pharmaceuticals Successfully Doses First Patients in Phase 2 Clinical Trial for Glioblastoma Treatment - Defense World
Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial - Yahoo! Voices
"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs" - Marketscreener.com
SHPHShuttle Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals dips 6%, prices $3.5M share offering - MSN
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of - GlobeNewswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Benzinga
Shuttle Pharma Pays Off Senior Secured Convertible Note - GlobeNewswire
Micro Cap Soaring On Phase 2 Trial Update - Invezz
TSX American Preferred Stock Index (STNC) QuotePress Release - The Globe and Mail
US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial - TipRanks
Shuttle Pharma (SHPH) Stock Rises Pre-Market With Completion Site Enrollments - Stocks Telegraph
Shuttle Pharma Doses First Patients in Phase 2 Clinical - GlobeNewswire
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Yahoo Finance
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update - MarketWatch
Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials - TipRanks
Shuttle Pharma Completes Clinical Trial Site Enrollment for - GlobeNewswire
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharmaceuticals to Present at ThinkEquity Conference - TipRanks
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - GlobeNewswire
Shuttle Pharmaceuticals completes funding round, raises $790,000 By Investing.com - Investing.com Canada
Finanzdaten der Shuttle Pharmaceuticals Holdings Inc-Aktie (SHPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.58%
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):